Gujrathi Sheila's Form 4 filing
Ventyx Biosciences, Inc. (VTYX) · filed Dec 26, 2024
- Accession no.
- 0001415889-24-030180
- Filed
- Dec 26, 2024
- Trade date
- Dec 23, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $300.3K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gujrathi SheilaCIK 0001575202 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2024 | Common Stock | PPurchaseAcquired | +130,000 | $2.31F1 | +$300,300 | 130,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average share price of an aggregate total of 130,000 shares purchased in the price range of $2.275 to $2.38. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.